Could Catalent Inc (NYSE:CTLT) Change Direction After More Shorts?

June 29, 2018 - By Gary Horn

Catalent, Inc. (NYSE:CTLT) Logo

Investors sentiment decreased to 1.16 in Q1 2018. Its down 0.28, from 1.44 in 2017Q4. It fall, as 23 investors sold Catalent, Inc. shares while 85 reduced holdings. 37 funds opened positions while 88 raised stakes. 127.42 million shares or 2.50% less from 130.69 million shares in 2017Q4 were reported.
First Mercantile Trust holds 3,120 shares. Ameritas Investment Prtnrs holds 51,163 shares. Natixis owns 208,067 shares. Invesco owns 1.30M shares or 0.02% of their US portfolio. Campbell Co Adviser Ltd Liability Co owns 0.36% invested in Catalent, Inc. (NYSE:CTLT) for 10,529 shares. 317,600 were accumulated by Renaissance Technologies Lc. Hsbc Holdings Public Limited Co owns 67,180 shares or 0% of their US portfolio. California Public Employees Retirement Sys invested in 260,552 shares or 0.02% of the stock. Impax Asset Mngmt Lc owns 433,796 shares for 1.03% of their portfolio. Captrust Advsrs accumulated 2,978 shares. Cornerstone has invested 0% in Catalent, Inc. (NYSE:CTLT). Ellington Management Llc stated it has 0.04% in Catalent, Inc. (NYSE:CTLT). The Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Catalent, Inc. (NYSE:CTLT). Shine Invest Advisory Services reported 0.01% of its portfolio in Catalent, Inc. (NYSE:CTLT). State Treasurer State Of Michigan holds 0.02% of its portfolio in Catalent, Inc. (NYSE:CTLT) for 48,600 shares.

Since March 8, 2018, it had 0 insider buys, and 2 insider sales for $473,717 activity. Another trade for 9,082 shares valued at $379,628 was made by Downie William on Thursday, March 8.

The stock of Catalent Inc (NYSE:CTLT) registered an increase of 10.59% in short interest. CTLT’s total short interest was 3.19M shares in June as published by FINRA. Its up 10.59% from 2.89 million shares, reported previously. With 678,600 shares average volume, it will take short sellers 5 days to cover their CTLT’s short positions.

The stock increased 2.45% or $1.01 during the last trading session, reaching $42.27. About 336,167 shares traded. Catalent, Inc. (NYSE:CTLT) has risen 9.81% since June 29, 2017 and is uptrending. It has underperformed by 2.76% the S&P500.

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. The company has market cap of $5.64 billion. It operates through three divisions: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. It has a 87.33 P/E ratio. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Catalent, Inc. (NYSE:CTLT) Ratings Coverage

Among 8 analysts covering Catalent (NYSE:CTLT), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Catalent has $50 highest and $44.0 lowest target. $47.20’s average target is 11.66% above currents $42.27 stock price. Catalent had 8 analyst reports since January 8, 2018 according to SRatingsIntel. The rating was upgraded by KeyBanc Capital Markets on Wednesday, March 28 to “Overweight”. The company was downgraded on Tuesday, February 6 by Stephens. As per Wednesday, March 21, the company rating was upgraded by Raymond James. The company was maintained on Tuesday, February 6 by Bank of America. The company was maintained on Monday, February 5 by Jefferies. The firm has “Buy” rating given on Monday, February 5 by RBC Capital Markets.

Another recent and important Catalent, Inc. (NYSE:CTLT) news was published by Globenewswire.com which published an article titled: “Investor Expectations to Drive Momentum within AMC Entertainment, Arrowhead Pharmaceuticals, US Silica, Catalent …” on June 26, 2018.

Catalent, Inc. (NYSE:CTLT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.